High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment
- PMID: 33710839
- PMCID: PMC8083848
- DOI: 10.5935/1518-0557.20200094
High anti-Müllerian hormone levels might not reflect the likelihood of clinical pregnancy rate in IVF/ICSI treatment
Abstract
Objective: To investigate if high anti-Müllerian hormone (AMH) concentration is a useful tool to predict the outcome of assisted reproductive treatment.
Methods: Retrospective cohort study involving 520 patients who underwent IVF/ICSI procedures in a university hospital. We measured the serum AMH level on day 3 of the menstrual cycle. Based on AMH levels, we divided the patients into three groups as follows: low (<25th percentile) AMH group, average (25th to 75th percentile) AMH group and high (>75th percentile) AMH group. We recorded the fertilization rate (FR), the number of oocytes retrieved, the number of good quality embryos (GQEs) and the clinical pregnancy rate (CPR).
Results: There was no difference between the three AMH groups in terms of maternal age, body mass index (BMI), follicle-stimulating hormone (FSH), estradiol (E2), luteinizing hormone (LH) and testosterone (T) in the IVF/ICSI cycles. The women in the high serum AMH group had a higher number of retrieved oocytes than those in the low or average AMH groups (p < 0.01) in the IVF/ICSI cycles. Compared with the low or average AMH groups, the women with high AMH levels had a higher number of good quality embryos (GQEs) in the IVF/ICSI cycles (p < 0.01). However, high AMH women had no significantly higher clinical pregnancy rate (CPR) compared to the women in the low or average AMH groups. In addition, for the prediction of CPR, the AMH levels alone were not an independent predictor of CPR for IVF and ICSI cycles in the ROC curve analysis.
Conclusions: High anti-Müllerian hormone levels are an independent predictor of the number of retrieved oocytes and good quality embryos (GQEs), but might not reflect the likelihood of higher clinical pregnancy rates (CPR) in IVF/ICSI treatment.
Keywords: IVF/ICSI; anti-Müllerian hormone (AMH); clinical pregnancy rate (CPR); good quality embryos (GQEs); number of retrieved oocytes.
Conflict of interest statement
All authors declare that they have no competing interests.
Figures
Similar articles
-
High Serum Anti-Müllerian Hormone Concentrations Are Associated With Poor Pregnancy Outcome in Fresh IVF/ICSI Cycle but Not Cumulative Live Birth Rate in PCOS Patients.Front Endocrinol (Lausanne). 2021 May 26;12:673284. doi: 10.3389/fendo.2021.673284. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34122349 Free PMC article.
-
AMH has no role in predicting oocyte quality in women with advanced age undergoing IVF/ICSI cycles.Sci Rep. 2020 Nov 12;10(1):19750. doi: 10.1038/s41598-020-76543-y. Sci Rep. 2020. PMID: 33184364 Free PMC article.
-
Low anti-Müllerian hormone level is not a risk factor for early pregnancy loss in IVF/ICSI treatment.Hum Reprod. 2020 Mar 27;35(3):504-515. doi: 10.1093/humrep/deaa008. Hum Reprod. 2020. PMID: 32219343
-
Can Ratios Between Prognostic Factors Predict the Clinical Pregnancy Rate in an IVF/ICSI Program with a GnRH Agonist-FSH/hMG Protocol? An Assessment of 2421 Embryo Transfers, and a Review of the Literature.Reprod Sci. 2021 Feb;28(2):495-509. doi: 10.1007/s43032-020-00307-2. Epub 2020 Sep 4. Reprod Sci. 2021. PMID: 32886340 Review.
-
The Value of Anti-Müllerian Hormone in the Prediction of Spontaneous Pregnancy: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne). 2021 Oct 13;12:695157. doi: 10.3389/fendo.2021.695157. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34721287 Free PMC article.
Cited by
-
Elevated Anti-Müllerian Hormone as a Prognostic Factor for Poor Outcomes of In Vitro Fertilization in Women with Polycystic Ovary Syndrome.Biomedicines. 2023 Nov 27;11(12):3150. doi: 10.3390/biomedicines11123150. Biomedicines. 2023. PMID: 38137371 Free PMC article.
-
Predictors of Pregnancy after Artificial Insemination in Women with Polycystic Ovary Syndrome.JBRA Assist Reprod. 2025 Jul 30;29(2):201-210. doi: 10.5935/1518-0557.20240095. JBRA Assist Reprod. 2025. PMID: 39983029 Free PMC article.
-
A highly sensitive Anti-Müllerian hormone test as a promising tool for follicle growth prediction in primary ovarian insufficiency patients.Sci Rep. 2025 Apr 23;15(1):14005. doi: 10.1038/s41598-025-98808-0. Sci Rep. 2025. PMID: 40263374 Free PMC article.
-
Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.Arch Gynecol Obstet. 2023 Jul;308(1):43-61. doi: 10.1007/s00404-022-06683-1. Epub 2022 Jul 30. Arch Gynecol Obstet. 2023. PMID: 35907969
-
Association between anti-Müllerian hormone levels during pregnancy and pregnancy outcomes in infertile patients undergoing in vitro fertilisation/intracytoplasmic sperm injection: protocol for a multicentre prospective cohort study.BMJ Open. 2025 Jun 10;15(6):e093543. doi: 10.1136/bmjopen-2024-093543. BMJ Open. 2025. PMID: 40499959 Free PMC article.
References
-
- Broer SL, Dólleman M, Van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PM, Eijkemans MJ, Mol BW, Broekmans FJ, IPD-EXPORT Study Group Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil Steril. 2013;100:420–9.e7. doi: 10.1016/j.fertnstert.2013.04.024. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources